Daily Anesthesiology Research Analysis
Analyzed 90 papers and selected 3 impactful papers.
Summary
Analyzed 90 papers and selected 3 impactful articles.
Selected Articles
1. Hypothalamic clock governs circadian pain.
This study demonstrates that nociceptive thresholds oscillate across the day in a mouse neuropathic pain model and identifies a rhythmic circuit from the hypothalamic suprachiasmatic nucleus (SCN) to descending analgesia that drives this pattern. Elevated daytime VIP neuron activity in SCN is implicated, linking the central circadian clock to pain modulation.
Impact: Revealing a circuit-level mechanism for circadian pain bridges chronobiology and analgesia, opening avenues for time-of-day–tailored therapies and novel targets (e.g., VIP-SCN pathways).
Clinical Implications: Suggests potential for chrono-analgesia: aligning dosing of analgesics or neuromodulatory interventions with circadian pain peaks, and exploring SCN/VIP-targeted strategies.
Key Findings
- Nociceptive thresholds show daily oscillations in a mouse neuropathic pain model.
- A rhythmic circuit from the hypothalamic SCN to the descending analgesia system drives circadian pain.
- Daytime (resting phase) features higher SCN VIP neuron activity linked to analgesic control.
Methodological Strengths
- Circuit-level mechanistic mapping linking central clock to pain pathways in vivo
- Temporal profiling across the circadian cycle in a validated neuropathic model
Limitations
- Findings are derived from mouse models and require validation in humans.
- Abstracted details on specific downstream nuclei and causal manipulations are limited.
Future Directions: Translate to human studies to test time-of-day–dependent analgesic efficacy; dissect SCN-descending pathway nodes for therapeutic targeting.
Chronic pain exhibits circadian rhythms in humans, but the mechanisms underlying such rhythmicity remain unclear. Here, we found daily oscillations in the nociceptive thresholds in a mouse model of neuropathic pain, driven by a rhythmic circuit from the master clock in the hypothalamus to the descending analgesia system. In the daytime (resting phase), higher vasoactive intestinal peptide (VIP) neuronal activity in suprachiasmatic nucleus (SCN
2. Elucidation of a potent pro-resolving mediator of inflammation resolution via human neutrophil-vascular endothelial cell interactions.
The authors identify a previously unknown DHA-derived specialized pro-resolving mediator, 4,13-diHDHA (4S,13R-diHDHA), generated via endothelial COX-2 and neutrophil 5-LOX crosstalk. Structural elucidation and recombinant enzyme validation support its biosynthesis, and the lipid exerts nanomolar pro-resolving actions across multiple human and mouse systems.
Impact: Defines a new pro-resolving lipid pathway at the leukocyte–endothelial interface with multi-system validation, offering mechanistic and therapeutic leads for controlling excessive inflammation.
Clinical Implications: Supports development of resolution-based therapeutics (e.g., SPM analogs) that could reduce inflammatory injury in perioperative, critical care, or cardiovascular settings.
Key Findings
- Discovery and structural elucidation of a novel DHA-derived mediator, 4,13-diHDHA (4S,13R), produced via endothelial COX-2 and neutrophil 5-LOX crosstalk.
- Nanomolar pro-resolving actions include limiting neutrophil infiltration, reducing neutrophil–endothelial adhesion, protecting endothelial cells from senescence, and stimulating macrophage efferocytosis.
- Metabololipidomics and recombinant enzyme studies validate biosynthetic pathways during leukocyte–vascular interactions.
Methodological Strengths
- Integrated metabololipidomics with structural validation (MS/MS, UV, deuterated substrates)
- Cross-system validation in human cells, mouse in vivo models, and recombinant enzymes
Limitations
- Preclinical validation; clinical efficacy and safety in humans are unknown.
- Quantitative pharmacokinetics and stability in vivo require further characterization.
Future Directions: Optimize stable analogs and delivery, delineate receptor targets, and test efficacy in disease models relevant to perioperative or critical care inflammation.
The acute inflammatory response is a highly coordinated programmed sequence that enables neutrophils to transmigrate from venules into tissues. Ideally self-limited, the active resolution phase produces specialized molecules that stimulate resolution and prevent collateral tissue damage from excessive neutrophil infiltration. The superfamily of pro-resolving molecules is termed specialized pro-resolving mediators including the essential polyunsaturated fatty acid-derived lipoxins, resolvins, protectins, and maresins. Given the intimate interactions between leukocytes and endothelial cells in inflammation resolution, we investigated whether unique bioactive molecules carrying pro-resolution properties are biosynthesized by human neutrophils coincubated with activated vascular endothelial cells. Using metabololipidomics, we found that human coronary aortic valves from transplants contained 13-hydroxy-4Z,7Z,10Z,14E,16Z,19Z-docosahexaenoic acid (13-HDHA) and inflammatory eicosanoids. We report that human endothelial cells convert DHA to 13-HDHA which in turn is transformed by human neutrophils to a previously unknown bioactive product 4,13-dihydroxy-docosahexaenoic acid. This structure was established using physical properties including tandem-mass spectrometry, UV-analysis, and conversion of deuterated substrate. Biosynthesis of this product during neutrophil-endothelial coincubations involved bidirectional crosstalk between neutrophil 5-LOX and endothelial COX-2 as confirmed using isolated recombinant enzymes. The bioactive 4S,13R-dihydroxy-5E,7Z,10Z,14E,16Z,19Z-docosahexaenoic acid, also produced by M2-like macrophages and mononuclear cells, demonstrated potent nanomolar pro-resolving actions including, a) limiting neutrophil infiltration into mouse air pouch, b) reducing human neutrophil adherence to endothelial cells, c) protecting endothelial cell from senescence, and d) stimulating human macrophage efferocytosis of senescent red blood cells. These results provide evidence for a previously unknown pro-resolving pathway and molecule biosynthesized from DHA via cyclooxygenase-2-5-lipoxygenase during leukocyte crosstalk with the vasculature.
3. Efficacy and Safety of Remimazolam Tosylate versus Propofol for Sedation of Postoperative Mechanically Ventilated Patients in Intensive Care Units: a Multicenter, Randomized, Single-blind, Non-inferiority, Phase 3 trial.
In 211 postoperative ventilated ICU patients, remimazolam achieved non-inferior sedation success to propofol (98.1% vs 96.2%) with similar time in RASS target, fewer additional boluses, and good tolerability over a mean 11–12 h treatment. Pharmacokinetics showed a mean terminal half-life of ~2 hours.
Impact: Provides phase 3 evidence positioning remimazolam as an alternative to propofol for short-term ICU sedation with high success and manageable dosing.
Clinical Implications: Supports adopting remimazolam for short-duration postoperative ICU sedation, especially when dose titration simplicity and benzodiazepine-based profiles are preferred.
Key Findings
- Non-inferior sedation success: 98.1% (remimazolam) vs 96.2% (propofol), difference 1.9% (95% CI −3.3% to 7.8%).
- Similar time in target RASS (≈95%); fewer additional doses with remimazolam (0.03±0.17 vs 0.18±0.77).
- Adverse events were mostly mild–moderate; one severe AE in propofol arm; remimazolam terminal half-life ~1.97 h.
Methodological Strengths
- Multicenter randomized, registered phase 3 non-inferiority design with active control
- Predefined outcome (sedation success) and standardized RASS targets
Limitations
- Single-blind design; maximum 24-hour treatment limits generalizability to prolonged ICU sedation.
- Predominantly postoperative population (≈99%) may limit applicability to medical ICU cohorts.
Future Directions: Assess performance in prolonged sedation, non-postoperative ICU populations, and comparative hemodynamic and delirium outcomes.
BACKGROUND: Remimazolam tosylate, a novel short-acting benzodiazepine, has shown effective and safe sedation in mechanically ventilated patients in intensive care units (ICU) in a phase 2 trial. We conducted a multicenter, randomized, single-blind, actively controlled, phase 3 trial (NCT06222294) for further evaluation. METHODS: Mechanically ventilated patients, requiring sedation for ≥6 h with a target Richmond Agitation-Sedation Scale (RASS) of -2 to 1, were randomized (1:1) to receive intravenous remimazolam tosylate (loading dose, 0.08 mg/kg; maintenance, 0-2.0 mg/kg/h) or propofol (loading dose, 0.3-0.5 mg/kg; maintenance, 0.3-4.0 mg/kg/h). Both allowed for adjusted infusion rates or additional doses to maintain target RASS. Maximum treatment duration was 24 h. Primary endpoint was proportion of patients achieving sedation success, defined as maintaining target sedation range for ≥70% of drug administration time without rescue sedation. Non-inferiority margin was -8%. RESULTS: Between Mar. 12, 2024 and Sep. 24, 2024, 211 patients (mean age, 61.1 years; 63.5% male; 99.1% postoperative) received remimazolam tosylate (n=106) or propofol (n=105). Mean (SD) treatment duration was 11.5±3.6 h for remimazolam tosylate and 11.1±3.1 h for propofol; mean (SD) total dose was 187.1±134.4 mg and 593.7±530.9 mg, respectively. Sedation success rate was 98.1% with remimazolam tosylate and 96.2% with propofol (difference 1.9%, 95% CI -3.3% to 7.8%); mean (SD) percentage of time in RASS target range was 95.1±13.8% vs 95.0±12.9%, and proportion of patients receiving rescue sedation was 0.0% (0/106) vs 1.0% (1/105). Mean (SD) additional doses required was 0.03±0.17 for remimazolam tosylate and 0.18±0.77 for propofol. Adverse event occurred in 81 (76.4%) patients with remimazolam tosylate and 77 (73.3%) with propofol; all were mild-moderate, except one severe with propofol. Mean terminal half-life (SD) of remimazolam tosylate was 1.97±1.62 h. CONCLUSIONS: Remimazolam tosylate demonstrated non-inferior efficacy and good tolerability compared with propofol for short-term sedation in postoperative mechanically ventilated ICU patients.